オプションチェーンは、Abbott Laboratoriesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Abbott Laboratoriesの市場センチメントを評価します。.

Abbott Laboratories (NYSE:ABT) 株価情報, オプションチェーン

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

ABBOTT LABORATORIES ORD

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $129.93, a high estimate of $149.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 4.91% increase from the previous average price target of $123.85.
<img src="https://www.benzinga.com/files/images/story/2024/1730818870_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Abbott Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Abbott Laboratories's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Abbott Laboratories's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Financial Insights: Abbott Laboratories</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Abbott Laboratories displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.85%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Abbott Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 15.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Abbott Laboratories

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

News

Price Target

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Reducing Need For Repeat Procedures By 48% Compared To Balloon Angioplasty; New Data From LIFE-BTK Trial Presented At VIVA 2024
<a href="https://abbott.mediaroom.com/press-releases?item=124676" title="https://abbott.mediaroom.com/press-releases?item=124676">https://abbott.mediaroom.com/press-releases?item=124676</a>

Biotech

General

Abbott's Esprit BTK System Shows Sustained Two-Year Benefits For Treating Severe Peripheral Artery Disease Below The Knee

WIIM

Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy. It was the companies' first trial win in litigation over the products.
<a href="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial" title="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial">https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial</a>

RBGLY

Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks

<ul>
<li>The first-of-its-kind TEAM-HF study seeks to improve clinical outcomes in patients with worsening heart failure
<ul>
<li>Trial establishes new, objective criteria to identify patients most at risk for developing end-stage heart failure and potentially offer life-saving therapeutic options sooner in their disease progression</li>
</ul>
</li>
</ul>

Abbott Initiates First-Of-Its0Kind Clinical Trial To Improve Outcomes Patients With Advanced Heart Failure

In the current market session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) stock price is at $116.19, after a 0.68% decrease. However, over the past month, the company's stock increased by 2.51%, and in the past year, by 24.17%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_0.png" alt="Past Year Chart" />

<h3>Abbott Laboratories P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Abbott Laboratories has a lower P/E than the aggregate P/E of 265.82 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729618243_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

P/E Ratio Insights for Abbott Laboratories

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

On Wednesday,&nbsp;Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $10.55 billion</a>.
Organic sales growth for the underlying base business was 8.2%, led by double-digit&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-" rel="noreferrer noopener">growth in Medical Devices</a>. Abbott&#8217;s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.
Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus&nbsp;<a target="_blank" href="https://www.benzinga.com/24/07/39839507/abbott-laboratories-q2-earnings-revenue-and-profit-beat-estimates-nudges-up-annual-profit-guidance-o" rel="noreferrer noopener">prior guidance of $4.61-$4.71</a> and consensus of $4.66. It forecasts fourth-quarter adjusted EPS of $1.31-$1.37 versus the consensus of $1.20.
William Blair anticipates that Abbott will return to a more typical pattern of double-digit earnings growth in the fourth quarter, a trend that is expected to continue into 2025 as the company moves past the impacts of the &#8220;COVID-cloud&#8221; management mentioned earlier.
Looking ahead to 2025, the analyst writes that Abbott has built a robust pipeline of products poised to drive a high-single-digit growth rate, an acceleration compared to pre-COVID levels.
William Blair notes that the investment landscape remains attractive, particularly given Abbott&#8217;s valuation compared to other large-cap MedTech peers experiencing similar growth.
The analyst anticipates a potential upside in EPS if macroeconomic headwinds diminish in the coming quarters, viewing 2024 as a transitional year leading to a resurgence in low-double-digit earnings growth by 2025.
Given that the stock is currently trading at 22.8 times William Blair&#8217;s 2025 EPS estimate of $5.16, the analyst maintains an <a href="https://www.benzinga.com/quote/ABT/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform rating on Abbott</a>.
<h2 class="wp-block-heading">Abbott Laboratories Stock Prediction For 2024</h2>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Abbott Laboratories, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Abbott Laboratories, the 200-day moving average sits at $110.38, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $117.31. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: ABT stock is down 0.22% at $117.56 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41385280/universal-stainless-finds-new-home-as-luxembourg-based-aperam-makes-big-us-move-details" target="_blank" rel="noreferrer noopener">Universal Stainless Finds New Home As Luxembourg-Based Aperam Makes Big US Move: Details</a>.</li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

Trading Ideas

Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic

There are many reasons to own Abbott Laboratories (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/abt#NYSE">ABT</a>), but they all boil down to one thing: consistent market-beating returns. A study published by Hendrik Bessembinder, a professor of finance at Arizona State University, found that Abbott is the 11th top-returning stock since 1937 and #1 among healthcare names.&nbsp;
The critical takeaways from the report are time and consistency: the top performers produce slower annual growth than flash-in-the-pan growth stories but do it year in and year out, compounding value over the long term. Value is driven by company growth, cash flow, and capital returns, which, in Abbott&#39;s case, include dividends and share repurchases. Abbott stock can also help reduce portfolio risk because its low beta is about 0.7x the S&amp;P 500.
<h2>High-Quality Abbott Stock: Corporate Growth That Pays You to Own It</h2>
Abbott Laboratories had a solid Q3, reporting 4.9% growth to outpace the consensus forecast despite the impact of lower COVID-related sales and discontinued business. Organically, ongoing business grew by 8.2% due to strength in the medical device segment. Medical Devices grew by 11.7% reported and 13.3% organic due to a double-digit increase in Structural Heart and Heart Failure and the release of continuous glucose monitors, showing the strength of the diversified portfolio.&nbsp;
Regarding the remaining segments, established Pharmaceuticals grew by 2.7% on a reported basis and 7% organically, offset by reported declines in Nutrition and Diagnostics. Nutrition contracted by 0.3% as reported but grew by 3.4% organically, while Diagnostics declined by 1.3% on a reported basis but grew by 1.4% organically.&nbsp;
Margin news is also solid, sustaining the outlook for balance sheet health and capital returns. The company&#39;s operating and net margin widened slightly compared to the previous year, driving earnings leverage. The operating and net operating earnings are up 12.8% and 14.6%, leaving the adjusted fully diluted EPS at $1.21 or up 6%, with margins forecasted to remain stable in Q4.&nbsp;
Abbott&#39;s guidance is favorable in that revenue targets were reaffirmed, and the mid-point for earnings was raised. The company expects full-year earnings in a range centering on $4.67 versus the $4.66 consensus, which should keep the analysts happy and support the uptrend in share prices.&nbsp;
<h2>Abbott Laboratories Capital Return Grows Safely, Drives Value for Shareholders</h2>
Abbott Laboratories&#39; capital return is safe and reliable, with a 53-year history of sustained annual increases and a low payout ratio below 50%. The balance sheet is a fortress with no red flags, leaving ample cash flow for R&amp;D, reinvestment, acquisitional cash flow, and share repurchases. Repurchase activity isn&#39;t robust but sufficient to offset dilutive forces and reduce the count annually. Highlights from Q3 include a 0.05% YTD share count reduction and a freshly amended repurchase authorization worth $7 billion or about 3.5% of the market cap before the release.&nbsp;&nbsp;
Analysts&#39; support for Abbott is strong. The trend in calendar Q3 is increasing coverage, improving sentiment, and upward price target revisions. The consensus is a Moderate Buy verging on a Strong Buy with a price target of $125, about 10% above the post-release opening price. The freshest revisions lead to the high-end range, another 10% to 15% above the consensus target, and a new all-time high when reached.
<h2>Abbott Slips Into a Buying Opportunity</h2>
The price action following the release was tepid, with share prices pulling back slightly. However, analysts and institutions support the market well, so the pullback should result in a buying signal soon. The critical support target is near $115 and will likely be tested. If the market can sustain support above that level, a move to fresh highs is likely before the year&#39;s end. If not, Abbott Laboratories&#39; share price may remain range-bound until more is available.&nbsp;
<img alt="Abbott Laboratories ABT stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241016081501_chart-abt-10162024.png" style="height:448px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/abbotts-growth-and-dividends-make-it-a-smart-portfolio-pick/">Abbott&#39;s Growth and Dividends Make It a Smart Portfolio Pick</a>&quot; first appeared on MarketBeat.

Earnings

Large Cap

Guidance

Dividends

Technicals

Abbott's Growth and Dividends Make It a Smart Portfolio Pick

Bernstein analyst Lee Hambright maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and raises the price target from $133 to $138.

Bernstein Maintains Outperform on Abbott Laboratories, Raises Price Target to $138

UBS analyst Danielle Antalffy maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $143 to $146.

UBS Maintains Buy on Abbott Laboratories, Raises Price Target to $146

Jefferies analyst Matthew Taylor maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Hold and raises the price target from $120 to $125.

Jefferies Maintains Hold on Abbott Laboratories, Raises Price Target to $125

Mizuho analyst Anthony Petrone maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Neutral and raises the price target from $115 to $130.

Mizuho Maintains Neutral on Abbott Laboratories, Raises Price Target to $130

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41356487/abbott-laboratories-q3-earnings-revenue-and-eps-beat-company-says-well-positioned-to-achieve-upper-">results on Wednesday.</a>
The company posted sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion. Abbott&#8217;s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.
"Our results this quarter demonstrate the strength of our diversified business model," said Robert Ford, chairman and CEO of Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year."
Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus prior guidance of $4.61-$4.71 and consensus of $4.66. Abbott forecasts that in the fourth quarter of 2024, the adjusted EPS will be $1.31-$1.37 versus the consensus of $1.20.
Abbott shares gained 1.5% to close at $117.82 on Wednesday.
These analysts made changes to their price targets on Abbott following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/topic/david-lewis">Morgan Stanley analyst David Lewis</a> maintained Abbott with an Equal-Weight and raised the price target from $107 to $117.</li>
<li>Piper Sandler analyst Adam Maeder maintained the stock with an Overweight and boosted the price target from $131 to $133.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="512" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png" alt="" class="wp-image-600697" style="width:668px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-1024x512.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151-768x384.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17091351/image-151.png 1325w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is doing &#8220;very, very well.&#8221; However, he added that Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) remains his favorite in <a href="https://www.benzinga.com/quote/ABBV/analyst-ratings">the group right now</a>.
AbbVie was founded in 2013 when it became a separate company from Abbott.
On Oct. 9, UBS analyst Navin Jacob maintained AbbVie with a Neutral and raised the price target from $185 to $195.
When asked about Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), he said, &#8220;I like the prospects. But you're in it for the data center, and the data center business is excellent.&#8221;
Oracle recently launched Oracle Health Clinical Data Exchange, a cloud-based solution that streamlines medical claims processing through secure, automated data exchange between <a href="https://www.benzinga.com/markets/equities/24/10/41317667/oracle-streamlines-medical-claims-processing-with-cloud-based-solution">healthcare providers and payers</a>.
Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) is a &#8220;mini-Palantir,&#8221; Cramer said. He recommended buying Palantir (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>).
On Oct. 11, B. Riley Securities analyst Lucas Pipes maintained Core Scientific with a Buy and raised the price target from $13 to $14.
&#8220;I just don't want to go there. I know that it's a good company, but I just don't want to hurt anybody,&#8221; Cramer said when asked about Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>).
The company recent said the Centers for Medicare and Medicaid Services (CMS) increased the Star rating of its PPO Medicare Advantage plans to 4 Stars for 2025, affecting payments in 2026.
GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) is a &#8220;very valuable company,&#8221; the &#8220;Mad Money&#8221; host said. &#8220;Just hold on.&#8221;
GXO recently announced a new transport partnership with Matalan.
Cramer said he really likes Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), adding that it is &#8220;terrific.&#8221;
Sweetgreen will release financial results for the third quarter after the closing bell on Thursday, Nov. 7.
Price Action:
<ul>
<li>Oracle shares gained 0.4% to settle at $174.77 on Wednesday.</li>
<li>AbbVie shares fell 0.7% to close at $190.46.</li>
<li>Core Scientific shares gained 2.2% to close at $13.25 on Wednesday.</li>
<li>GXO Logistics shares gained 2.6% to settle at $62.95.</li>
<li>Sweetgreen shares fell 0.7% to close at $37.94 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ABBV

CLOV

Core Scientific, Inc. - Class A Common Stock

CORZ

ORCL

PLTR

AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham raised Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $40 to $45. Needham analyst Joshua Reilly maintained a Buy rating. Clear Secure shares gained 5.2% to close at $37.35 on Wednesday. See how other analysts view this stock.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) from $7 to $9. HC Wainwright &amp; Co. analyst Scott Buck maintained a Buy rating. Phunware shares climbed 17.6% to close at $6.34 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Jack Henry &amp; Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>) from $186 to $195. Baird analyst David Koning maintained a Neutral rating. Jack Henry &amp; Associates shares gained 0.5% to close at $185.67 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised O-I Glass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OI#NYSE">OI</a>) price target from $14 to $16. B of A Securities analyst George Staphos upgraded the stock from Neutral to Buy. O-I Glass shares fell 0.3% to close at $12.73 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) price target from $58 to $68. Deutsche Bank analyst Mark Devries maintained a Buy rating. Synchrony Financial shares gained 6.1% to close at $56.52 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $600 to $650. Mizuho analyst James Lee maintained an Outperform rating. Meta shares fell 1.6% to close at $576.79 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark raised the price target for DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) from $152 to $173. Benchmark analyst Mark Zgutowicz maintained a Buy rating. DoorDash shares gained 0.7% to settle at $149.86 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised Lennox International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>) price target from $575 to $650. Mizuho analyst Brett Linzey maintained an Outperform rating. Lennox International shares gained 0.9% to close at $600.54 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley increased the price target for Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) from $107 to $117. Morgan Stanley analyst David Lewis maintained an Equal-Weight rating. Abbott shares rose 1.5% to close at $117.82 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Ladenburg Thalmann cut Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) price target from $65.5 to $60.5. Ladenburg Thalmann analyst Paul Fremont downgraded the stock from Neutral to Sell. Spire shares closed at $65.56 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png" alt="" class="wp-image-600449" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/17075912/image-146.png 1335w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a></li>
</ul>

Pre-Market Outlook

DASH

JKHY

PHUN

Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday

Piper Sandler analyst Adam Maeder maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $131 to $133.

Piper Sandler Maintains Overweight on Abbott Laboratories, Raises Price Target to $133

Morgan Stanley analyst David Lewis maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Equal-Weight and raises the price target from $107 to $117.

Morgan Stanley Maintains Equal-Weight on Abbott Laboratories, Raises Price Target to $117

Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a <a href="https://www.benzinga.com/topic/regional-banks">strong rally in regional banks. </a>
Financial stocks continued their upward momentum, buoyed by strong earnings reports. Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) significantly beat expectations, propelling its stock up by 8% to new all-time highs.
Regional banks, as tracked by the SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>), rallied 2.1%, hitting levels last seen in early March 2023, prior to the fallout of Silicon Valley Bank.
Airlines also soared, with United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) posting an 11% rally. The surge lifted the entire industry, as tracked by the U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>), which reached its highest level since July 2023.
The tech sector lagged, weighed down by weak performance in semiconductors. The industry was still reeling from ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)&#8217;s earnings shock on Tuesday, after the company slashed its 2025 revenue outlook, triggering a broad selloff in chipmakers.
Both the Nasdaq 100 and semiconductor stocks remained flat on Wednesday.
In the currency market, the U.S. Dollar Index was poised to log its 12th positive day in the last 13 sessions. Treasury yields edged lower. Oil prices saw a slight decline of 0.6%, with West Texas Intermediate (WTI) crude falling below $70 per barrel.
Precious metals offered positive signals, with gold set to close its fifth consecutive day of gains, while silver rose 0.8%.
In the cryptocurrency space, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advanced 1%, reaching $68,000 — its highest level since late July 2024.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,289.65</td>
<td>1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,981.53</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,830.29</td>
<td>0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,131.29</td>
<td>-0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent101624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.2% to $580.82.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;inched 0.6% higher to $429.93.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $489.94.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.8% to $226.77.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.4%. The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h3>
<ul>
<li>Interactive Brokers Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) fell over 3% after missing earnings estimate. </li>
<li>Other stocks reactive to company earnings included United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>), up 11.5%, J.B. Hunt Transport Services Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>), up 3.5%, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), up 1.7%, Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>), up 7.6%, U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>), up 4.7% and Citizens Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>).</li>
<li>ASML Holding N.V. fell over 5% after dropping 17% on Tuesday in reaction to dismal revenue outlook. </li>
<li>Companies set to report their earnings after the close include CSX Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), Kinder Morgan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>), Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>), Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) and Alcoa Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>). </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41356469/mortgage-demand-sees-sharpest-weekly-drop-since-april-2020-as-rates-climb-above-6">Mortgage Demand Sees Sharpest Weekly Drop Since April 2020 As Rates Climb Above 6.5%</a></li>
</ul>
Photo via Shutterstock.

Equities

Macro Economic Events

Sector ETFs

Small Cap

Economics

Movers

Tech

ETFs

$BTC

ASML

SPDR Dow Jones Industrial Average ETF Trust

IBKR

JBHT

JETS

STLD

Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday?

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report), Abbott Laboratories...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT) and Merck & Company (MRK)

Wall Street Breakfast Podcast: Boeing Aims To Land Union Deal...Again

The medical devices industry is on the verge of an incoming boom, fueled by its growing demand and technological advancements. In this evolving landscape, investors could scoop up shares of robust medical device stocks Alcon (ALC), Becton, Dickinson (BDX), and Abbott (ABT) for solid gains. Read more… As innovation continues to shape nearly every industry, the medical sector is no exception. Thanks to cutting-edge technology and AI integration, the industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics and surgeries.
Given this backdrop, investors looking for growth opportunities could invest in fundamentally sound medical device stocks Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>), Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>).
The medical devices industry is on the cusp of significant growth, driven by advancements in technology, increasing healthcare needs, and rising aging populations. Emerging trends like artificial intelligence, robotics, and telemedicine are reshaping how healthcare is delivered, offering more efficient, personalized, and accessible solutions for patients worldwide.
That said, AI has been a game-changer in the industry, driving breakthroughs in predictive diagnostics, remote monitoring, and precision medicine. Innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care.
The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, enhancing the industry's potential. These technologies promise faster diagnoses, more precise treatments, and significantly improved patient outcomes, positioning AI as a cornerstone in the future of healthcare innovation.
According to a study by KPMG, global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion by 2030</a>. Moreover, as per a study by Mordor Intelligence, the medical devices industry is poised for steady growth as its market size is anticipated to reach $893.07 billion by 2029, exhibiting a <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">CAGR of 7%</a>.
Considering these optimistic trends, let's take a look at three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry stocks in detail, beginning with #3.
Stock #3: Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>)
Headquartered in Geneva, Switzerland, is an eye care company that offers a range of products through two key segments: Surgical and Vision Care. The Surgical business focuses on ophthalmic products for cataract surgery, while the Vision Care business offers contact lenses and ocular health products.
On September 6, ALC <a href="https://investor.alcon.com/news-and-events/press-releases/news-details/2024/Alcon-Debuts-Latest-Digital-Innovations-SMARTCataract-DX-and-NGENUITY-1.5-at-ESCRS-2024-y6dT6v9S06/default.aspx">unveiled its latest innovations</a> at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting. The SMARTCataract DX digital planning solution, powered by the ARGOS&#xAE; Biometer, enhances workflow efficiency for practices, positioning ALC as a key player in the eye care sector.
Additionally, ALC introduced the NGENUITY&#xAE; 1.5 with connectivity capabilities, enabling image-guided 3D cataract surgery with the ARGOS Biometer. This provides superior visualization, driving better outcomes. With the rising global demand for cataract surgeries, ALC's innovations would help meet growing needs while strengthening its industry leadership.
On July 1, ALC <a href="https://investor.alcon.com/news-and-events/press-releases/news-details/2024/Alcon-Completes-Acquisition-of-BELKIN-Vision-Expanding-Glaucoma-Portfolio-with-Direct-Selective-Laser-Trabeculoplasty-DSLT-Device---2024-F7U9xE-k6o/default.aspx">completed its acquisition</a> of BELKIN Vision for $81 million, including $65 million in cash. The acquisition expands ALC's glaucoma portfolio with BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) technology, securing robust growth opportunities and future advancements in eye care.
ALC's net sales and other revenues for the fiscal second quarter that ended June 30, 2024, increased 3.1% year-over-year to $2.50 billion. Its gross profit marginally grew from the year-ago value to $1.54 billion. The company's core net income totaled to $367 million and $0.74 per share, up 7.6% and 7.2% from the prior year's quarter, respectively.
Analysts expect ALC's revenue and EPS for the fiscal third quarter (which ended September 2024) to increase 6% and 12.7% year-over-year to $2.47 billion and $0.74, respectively. Also, the company surpassed the consensus EPS estimate in three of four trailing quarters.
Shares of ALC have surged 19.7% over the past six months and 26.3% over the past year to close the last trading session at $94.52.
ALC's bright prospects are mirrored in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ALC has an A grade for Stability and a B for Growth. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, the stock is ranked #36 out of 135 stocks.
<a href="https://stocknews.com/stock/ALC/">Click here</a> to access additional ALC ratings for Momentum, Sentiment, Value, and Quality.
Stock #2: Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX designs, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, and the general public. The business operates through three segments: BD Medical; BD Life Sciences; and BD Interventional.
On October 14, BDX <a href="https://investors.bd.com/news-events/press-releases/detail/854/bd-announces-new-robotics-solution-to-automate-standardize-single-cell-research">announced the commercial launch</a> of the first in a family of high-throughput, robotics-compatible reagent kits that enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies.
With advancements in robotics solutions, BDX could accelerate the pace of discovery in oncology and immunology and gather a significant market presence in the medical devices industry.
On September 18, BDX <a href="https://investors.bd.com/news-events/press-releases/detail/850/bd-expands-capacity-for-advanced-prefillable-syringes-and-enhances-injection-experience-for-the-next-generation-of-biologics">announced the commercial release</a> of the BDX Neopak XtraFlow Glass Prefillable Syringe and expanded production capacity for its BDX Neopak Glass Prefillable Syringe platform.
By scaling production, BDX is expected to strengthen its position in the prefillable syringe market, supporting the pharmaceutical industry's need for high-quality, efficient drug delivery systems.
During the fiscal third quarter that ended on June 30, 2024, BDX's adjusted revenues increased 3.7% year-over-year to $5.06 billion. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 9.7% from the prior year to $602 million.
Moreover, the company's net income was $487 million, reflecting a 19.7% year-over-year growth. Meanwhile, its adjusted EPS rose 18.2% from the previous year's quarter to $3.50.
Street expects BDX's revenue and EPS for the fiscal fourth quarter that ended September 2024 to increase 5.2% and 10.1% year-over-year to $5.35 billion and $3.77, respectively. In addition, the company surpassed the consensus EPS estimates in three of the trailing four quarters.
Over the past month, the stock has gained 3.9% to close the last trading session at $240.33.
BDX's POWR Ratings reflect its robust prospects. It has an overall rating of B, translating to a Buy in our proprietary system.
BDX has a B grade for Growth, Stability, and Sentiment. It is ranked #31 in the 135-stock Medical – Devices &amp; Equipment industry.
<a href="https://stocknews.com/stock/BDX/">Click here</a> to see BDX's ratings for Value, Momentum, and Quality.
Stock #1: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells a diverse range of healthcare products. The company operates in four segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices, delivering comprehensive solutions to address various healthcare needs globally.
On October 10, ABT <a href="https://abbott.mediaroom.com/2024-10-10-Abbott-Advances-Pulsed-Field-Ablation-Clinical-Studies-and-Launches-New-Technology-to-Support-Advanced-Cardiac-Mapping">announced significant milestones</a> to expand its pulsed field ablation (PFA) solutions in electrophysiology. The company completed early enrollment for the VOLT-AF IDE Study, supporting its Volt&#x2122; PFA System, and launched the FOCALFLEX trial to evaluate the TactiFlex&#x2122; Duo Ablation Catheter, Sensor Enabled&#x2122; (SE), for treating patients with paroxysmal atrial fibrillation.
Additionally, ABT received FDA clearance for its Advisor&#x2122; HD Grid X Mapping Catheter, Sensor Enabled&#x2122;, designed to enhance cardiac mapping for both PFA and radiofrequency (RF) ablation cases. The cutting-edge technology ensures precise visualization of cardiac anatomy, driving better outcomes in ablation procedures.
On September 5, ABT <a href="https://abbott.mediaroom.com/2024-09-05-Abbotts-Lingo-TM-Continuous-Glucose-Monitor-for-Health-and-Wellness-Now-Available-in-the-U-S">announced the U.S. launch</a> of its Lingo Continuous Glucose Monitor, a non-prescription system designed for individuals aiming to enhance their health and wellness through real-time glucose tracking and personalized insights.
With new innovations and FDA clearances, ABT is continuously trying to re-establish itself as a market leader in the pharma landscape and ensuring stable growth prospects for the company in the future.
ABT's net sales for the fiscal third quarter, which ended September 30, 2024, increased 4.9% year-over-year to $10.64 billion. Its operating earnings grew 12.8% from the year-ago value to $1.86 billion. Moreover, adjusted net earnings came in at $2.12 billion or $1.21 per share, up 6% and 6.1% from the prior year's period, respectively.
The consensus revenue estimate of $11.03 billion for the fiscal fourth quarter ending December 2024 reflects a rise of 7.8% year-over-year. Its EPS for the same period is expected to increase 12.8% from the prior year's period to $1.34. Moreover, ABT topped the consensus revenue and EPS estimates in all four trailing quarters.
Shares of ABT have surged 11.3% over the past six months and 28% over the past year to close the last trading session at $117.89.
ABT's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
ABT has a B grade for Stability and Sentiment. Within the same industry, it is ranked #19. To see ABT's Growth, Value, Momentum, and Quality ratings, <a href="https://stocknews.com/stock/ABT/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
&nbsp;
&nbsp;

<hr />
ABT shares were unchanged in premarket trading Friday. Year-to-date, ABT has gained 9.24%, versus a 23.68% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/abt-bdx-alc-3-medical-device-stocks-to-buy-for-consistent-growth/>3 Medical Device Stocks to Buy for Consistent Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks to Buy for Consistent Growth

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of $130.00. The...

Oppenheimer Sticks to Their Buy Rating for Abbott Laboratories (ABT)

Shares of British consumer goods company Reckitt Benckiser ($GB:RKT) rallied more than 8% as of writing, after winning a favorable ruling from a U....

Reckitt and Abbott Shares Rally on Baby Formula Lawsuit Win

Biggest stock movers Friday: AMZN, INTC, ABT, and more

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.

What You Missed On Wall Street This Past Friday

Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price target remains...

Abbott Laboratories' Legal Victory Strengthens Future Outlook and Supports Buy Rating

Barclays analyst Matt Miksic raised the firm's price target on Abbott (ABT) to $149 from $143 and keeps an Overweight rating on the shares. The fir...

Abbott price target raised to $149 from $143 at Barclays

Barclays raised the firm's price target on Abbott (ABT) to $149 from $143 and keeps an Overweight rating on the shares. After rallying on the heels...

Comments

Abbott Laboratories

Abbott Laboratories (ABT) オプション

Abbott Laboratories (NYSE:ABT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル